# Actuate Therapeutics

Source: https://onco.cc/companies/actuate-therapeutics/  
OnCo record `actuate-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Texas biotech developing elraglusib, a GSK-3 beta inhibitor that improved survival in a randomised phase 2 in metastatic pancreatic cancer.

## Summary

Actuate Therapeutics listed on Nasdaq in 2024 to fund elraglusib. Its lead programme is first-line metastatic pancreatic cancer with gemcitabine and nab-paclitaxel, where the Actuate 1801 Part 3B randomised phase 2 reported longer survival; the company is planning a confirmatory phase 3 and also studies the drug in Ewing sarcoma and other tumours.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- HQ: Fort Worth, Texas, United States
- Type: biotech
- Website: https://www.actuatetherapeutics.com

## Sources

- Official website: https://www.actuatetherapeutics.com

## Connected records

- cancers: [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Elraglusib](https://onco.cc/drugs/elraglusib/)

---
JSON: https://onco.cc/api/v1/entities/actuate-therapeutics.json